Shares in Alnylam were up almost 56% at one point yesterday, while rival Ionis saw its shares slump 9%. Shares in The Medicines Company were also up 5.7% thanks to an RNAi licensing deal with Alnylam.

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Alnylam (ALNY) to $385 from $384 and keeps a Buy rating on the shares. The firm said its 4Q24 report was uneventful following its ...

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $264.89.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $83.8 million in its fourth quarter. On a per-share basis, the Cambridge ...